Purpose: Current and future treatment modalities for Clostridium difficile-associated disease (CDAD) are reviewed. Conclusion: CDAD is a major concern for health care systems and clinicians.

What is in your differential diagnosis when considering recurrent C difficile infections? How is a definitive diagnosis made?

A: Animal; ACE: Accessory cholera enterotoxin; H: Human; ZOT: Zonula occludens toxin.

How does recurrent C difficile infection impact health care resources utilization and other medical costs? What are the ways in which recurrent C difficile infection can adversely impact a patient ...

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has submitted the Clinical Study Report to the U.S. Food ...

Highlights:New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum ...

Molson Coors Beverage Co. Cl A-4.43% $11.09B Molson Coors Beverage Co. Cl B 0.71% $11.09B ...

U.S. value stocks are tallying their longest losing streak on record. Why they could see a comeback in 2025.

“In fact, the bacterium that causes the disease, Clostridium perfringens, is ever-present in the environment and the ... In that case, the bacteria can multiply rapidly, produce toxins and kill a calf ...